Emory University’s Nektar Therapeutics NKTR Stock Holding History

Emory University’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10,171	Closed	-$1.87M	–	46
2016 Q4	$1.87M	Buy	+10,171	New	+$2.07M	1.84%	16

Other funds holding NKTR

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Emory University's NKTR Position: Q1 2017 in Review

Emory University sold out of Nektar Therapeutics (NKTR) in Q1 2017, closing a stake of 10,171 shares — an estimated $1.87M sold.

Emory University first reported a position in NKTR in Q4 2016 and held it in 1 quarter. The position peaked at $1.87M in Q4 2016. 201 funds tracked by Wall St. Rank hold NKTR as of Q1 2017.

Emory University reported no remaining Nektar Therapeutics position as of Q1 2017 after selling out during the quarter.
Emory University sold 10,171 Nektar Therapeutics shares in Q1 2017, an estimated $1.87M.
Emory University first reported a position in Nektar Therapeutics in Q4 2016 and held it in 1 quarter.
Emory University's Nektar Therapeutics position peaked at $1.87M in Q4 2016.
201 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2017.

Based on Emory University's 13F filing for Q1 2017, filed 11 May 2017.